Bipolar II disorder (BD II) is a highly prevalent yet frequently underdiagnosed psychiatric condition, affecting an estimated 1-2% of adults worldwide. Despite its significant clinical and socioeconomic burden, including elevated suicide risk, chronic functional impairment, and high rates of misdiagnosis BD II was only recognized recently in diagnostic manuals. The disorder is characterized by alternating depressive and hypomanic episodes, with depressive symptomatology predominating, which often leads clinicians to mistakenly diagnose major depressive disorders or anxiety disorders. Recognizing BD II is further complicated by high comorbidity with anxiety disorders, substance-use disorders, eating disorders, and personality disorders, as well as by controversies surrounding the definition and duration of hypomania. The absence of established regulatory guidelines for BD II–specific pharmacological trials, combined with the complexity of individualized treatment regimens, has hindered evidence-based therapeutic development. Emerging research supports the existence of a broader bipolar spectrum, suggesting a continuum between unipolar depression and bipolar disorders, with BD II occupying a central transitional position. Improved diagnostic accuracy, clinician training, and recognition of atypical depressive features and subsyndromal bipolar symptoms are critical for reducing misdiagnosis and improving patient outcomes. This paper reviews the diagnostic challenges, epidemiology, clinical features, and spectrum conceptualization of BD II, emphasizing the urgent need for enhanced clinical awareness and standardized assessment tools.

The diagnosis of bipolar II disorder remains a diagnostic challenge, although it has been recognized as a distinct entity for almost 40 years [1]. It took 20 years for it to be formally incorporated into the DSM-IV. This is reflected in the epidemiology, where the prevalence is estimated at between 5 and 8%, depending on the school of psychiatry rather than the country. But traditionally lifetime prevalence is approximately 1%-2% in the general population; with 12-month prevalence around 0.5%–1%. More recent publications present a starkly contrasting view. Bipolar II disorder is considered a myth by some [2], while others argue that it is not [3].

Classically BD II is characterized by the alternation of major depressive episodes with hypomanic episodes, which may occur rapidly or evolve more slowly, depending on the individual . Despite the severity and chronicity of this condition, it remains widely under-recognized not by general practitioners, who are often the first point of contact, but even by specialists in psychiatry [4]. This diagnostic challenge has profound consequences: untreated or misdiagnosed BD II often results in devastating socio-economic impairments, such as divorce, impulsive and excessive financial spending, loss of employment, bankruptcy, and even legal problems leading to imprisonment. Most critically, the risk of suicide in BD II is markedly elevated, often higher than in Bipolar I disorder or unipolar depression. Many individuals are mistakenly prescribed antidepressants or other medications that can aggravate symptoms, precipitate mixed states, or rapid cycling, and thereby worsen the course of illness.

Why bipolar II disorder is so difficult to diagnose.

The complexity of BD II diagnosis is tied to several overlapping clinical features and very high rates of psychiatric comorbidity [5]. Patients frequently present various anxiety disorders such as panic disorder, generalized anxiety disorder, and social anxiety disorder as well as recurrent depressive episodes [6].

Because depressive symptoms dominate the clinical picture, especially early in the illness, the most common initial diagnoses include recurrent major depression, dysthymia, or generalized anxiety disorder. It is now estimated that patients wait an average of ten years between the onset of symptoms and a correct bipolar diagnosis [7].

Compounding this delay is the lack of large-scale clinical trials specifically addressing BD II. Because of the historical reluctance to distinguish BD II from other mood disorders and because regulatory agencies have not yet provided clear guidelines for drug development in BD II, clinicians face a major therapeutic impasse [8]. Many patients require complex polypharmacy, often a combination of a mood stabilizer (lithium, valproate, carbamazepine, lamotrigine) and an antidepressant or antipsychotic. These individualized therapeutic strategies, although clinically necessary, complicate standardized research methodologies [9]. To address this global difficulty, collaborative efforts such as joint training programs for general practitioners developed with Australian colleagues have emerged to improve recognition and diagnosis of BD II in community settings [10].

Clinical characteristics and diagnostic challenges

BD II shares several diagnostic features with Major Depressive Disorder [MDD]: both require the presence of a current or past major depressive episode. The essential distinction, however, is the presence of current or past hypomanic episodes in BD II [11]. It was demonstrated the low inter-rater reliability of BD II diagnosis, highlighting the need for systematic assessment instruments. While BD I is usually diagnosed with relative ease due to overt manic episodes, BD II and its variants require more careful, longitudinal, and structured evaluation [12]. Among the major reasons for diagnostic inconsistency in BD II is that these patients could present features of atypical depression and lifelong history of anxiety states, bulimia, substance abuse and personality disorder. However, hypersomnia, weight gain and related atypical features often represent an important marker of BD II. Such features may serve as a clinical marker for BD II [13].

The controversy surrounding hypomania

The definition of hypomania remains a topic of debate. In European clinical practice, hypomania is often used loosely to refer to mild mania. However, in DSM-IV, hypomania is defined as a distinct period of elevated or irritable mood lasting at least four days, accompanied by observable behavioral changes [14]. Critics argue that this duration requirement is arbitrary and excludes clinically meaningful brief hypomanic states. On the other hand, hypomania can be defined as a milder form of mania. It is a period of persistently elevated, expansive, or irritable mood that lasts for at least four days and up to a week [15].

Studies using broader or modified definitions have found even higher prevalence of BD II. It was  reported that 5.3% of community volunteers met “hard criteria” (hypomania with consequences) while another 5.7% met “soft criteria” (hypomanic symptoms without major consequences), yielding a total prevalence of 11%. Notably, the two BD II subgroups differed significantly from MDD but not from each other, supporting the idea that they belong to a unified bipolar diagnostic category [16].

Bipolar II disorder and the mood disorder continuum

A critical unresolved question in modern psychiatry is whether psychiatric syndromes exist as discrete categories or lie along continuum-based spectrums. Growing evidence suggests the latter, particularly for the relationship between BD II and MDD [17]. Even a single bipolar symptom within a depressive episode such as irritability, racing thoughts, or psychomotor agitation may tip the diagnosis toward BD II. Recurrent MDD is especially likely to evolve into bipolarity over time [18].

Up to 40% of patients with recurrent MDD report significant lifetime hypomanic symptoms, despite never having been diagnosed with BD II [19]. Conversely, long-term follow-up studies of patients with diagnosed bipolar disorders show that depressive symptoms dominate the illness course far more frequently than manic or hypomanic symptoms [20], a pattern particularly pronounced in BD II. Furthermore, patients with unipolar depression who later convert to bipolarity commonly present with retarded depressions, characterized by hypersomnia, psychomotor slowing, lethargy, and, in some cases, psychotic features [21]. These findings strengthen the view that BD II may sit mid-continuum between unipolar depression and Bipolar I disorder.

The bipolars spectrum concept

Increasingly, researchers recognize that BD includes a broader spectrum of disorders than the traditional BD I and BD II classifications [22]. Debates surrounding the definition of pathological mood elevation and the reluctance to pathologize elevated or “high functioning” mood states have created challenges in defining the full bipolar spectrum. Young & Klerman [23] proposed six clinical states, while Akiskal & Pinto [24] proposed seven subtypes, encompassing milder or subsyndromal bipolar variants not captured by DSM-IV or ICD-10 .

Importantly, the bipolar spectrum model does not discard existing diagnostic categories but extends them, accommodating a wider range of mood dysregulations. This model also helps address the high rates of comorbidity seen in categorical systems by recognizing that many overlapping symptoms may reflect bipolarity rather than entirely separate disorders (25).

Family studies strongly support this spectrum. The relatives of BD probands show not only higher rates of full bipolar disorder but also increased prevalence of milder bipolar features and other psychiatric conditions [26]. A study reported that two-thirds of bipolar probands may fall somewhere within the bipolar spectrum [27].

Prevalence estimates for the broader bipolar spectrum range from 3% to 6.5% [28] and, in some studies, as high as 10–12% [29]. Remarkably, up to 30% of primary care patients presenting with anxiety and/or depressive symptoms meet criteria for a bipolar spectrum disorder [30]. Even subsyndromal depressive symptoms can lead to significant functional impairment for individuals on the bipolar spectrum [31].

The bipolar spectrum concept encompasses not only major episodes—mania, hypomania, and major depression but also mixed states, hyperthymic temperament, and depressive mixed states, characterized by severe irritability, racing thoughts, extreme fatigue, panic attacks, and suicidal impulses [32].

Hyperthymic temperament, often seen in BD II and bipolar spectrum disorders, is associated with high energy, sociability, ambition, and productivity but also with risk-taking behavior and interpersonal conflict [33]. These “milder” or temperament-based forms of bipolarity may in fact be more common than Bipolar I disorder [34].

The spectrum model also helps explain misdiagnosis and underdiagnosis. Patients frequently present with atypical depressions, lifelong anxiety, eating disorders, or substance misuse, which may obscure the underlying bipolarity. Recognizing these bipolar spectrum states may bridge the conceptual and diagnostic gap between unipolar and bipolar disorders, supporting the notion of a unified mood disorder continuum.

Bipolar II disorder remains a profoundly underrecognized and diagnostically challenging condition despite four decades of clinical acknowledgment. Its predominance of depressive episodes, high psychiatric comorbidity, and often subtle or retrospective hypomanic features contribute to frequent misclassification such as unipolar depression or anxiety disorders. These diagnostic complexities carry substantial clinical consequences, including prolonged delays to accurate diagnosis, inappropriate treatment with antidepressants, and heightened risks of chronic functional impairment and suicide.

Emerging research underscores that BD II rarely exists as an isolated phenotype; rather, it occupies a central position within a broader bipolar spectrum characterized by mixed features, subthreshold symptoms, hyperthymic temperaments, and atypical depressive presentations. This dimensional perspective provides a more comprehensive framework for understanding the heterogeneity of mood disorders and may help reconcile the inconsistencies inherent in strict categorical systems.

At the same time, the absence of regulatory guidance for BD II specific therapeutic trials and the prevailing reliance on individualized polypharmacy highlight the urgent need for more rigorous, standardized research. Improving diagnostic precision will depend on enhanced clinician training, systematic use of structured assessments, and increased awareness of atypical and mixed depressive features that frequently signal underlying bipolarity.

A better integration of spectrum-based models with contemporary diagnostic criteria, combined with sustained efforts to educate clinicians and refine treatment strategies, will be essential to reducing misdiagnosis and improving outcomes for the substantial number of individuals living with Bipolar II

disorder. Ultimately, recognizing BD II not as a rare or ambiguous variant but as a common, clinically impactful mood disorder is critical to advancing both research and patient care.